Spyre Therapeutics is a clinical-stage biotechnology firm developing next-generation antibody therapies for inflammatory bowel disease and other immune-mediated conditions. Its pipeline centers on extended half-life monoclonal antibodies against validated targets such as α4β7, TL1A and IL-23, including combination regimens aimed at deeper and more durable disease control. The company focuses on patients with ulcerative colitis, Crohn’s disease and related rheumatic indications, seeking simpler dosing and more complete response than existing biologics.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -44.8 | — |
| Q2 2025 | 0 | — | -36.7 | — |
| Q3 2025 | 0 | — | -11.2 | — |
| Q4 2025 | 0 | — | -62.5 | — |
| Q1 2026 | 0 | — | -69 | — |
| Q2 2026 | 0 | — | -36.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Zillow Group, Inc. (Z), GitLab Inc. (GTLB), FormFactor, Inc. (FORM), CAE Inc. (CAE), Kanzhun Limited (BZ), Central Bancompany, Inc. (CBC)